REMspace Secures $1M Seed Round to Propel Lucid Dreaming Innovation

REMspace, a pioneering neurotechnology firm dedicated to advancing the practice of lucid dreaming, has successfully closed a $1 million seed funding round. The investment, raised from prominent lucid dreaming practitioners and enthusiasts across Europe, positions REMspace to accelerate its mission of making lucid dreaming accessible on a global scale. Led by CEO Michael Raduga, REMspace…

Read More

Rapafusyn Pharmaceuticals Raises $28 Million to Revolutionize Drug Discovery with Innovative Molecular Glue Platform

Rapafusyn Pharmaceuticals, a trailblazer in the realm of therapeutic drug discovery, has announced a significant milestone with the closure of a Series A financing round, amassing $28 million. This strategic investment round was led by 3E Bioventures Capital and Proxima Ventures Ltd., with participation from Lapam Capital. Rapafusyn is spearheading the development of non-degrading molecular…

Read More

Codeium Achieves $1.25 Billion Valuation with $150 Million Series C Funding Led by General Catalyst

Codeium, a leading generative AI-powered coding platform, has announced the successful closure of a $150 million Series C funding round, elevating the company’s valuation to an impressive $1.25 billion. This funding round was spearheaded by General Catalyst, with continued backing from existing investors Kleiner Perkins and Greenoaks. With this new capital, Codeium solidifies its position…

Read More

Ancilia Biosciences Secures $4.2 Million in Financing to Advance CRISPR-Based Bacterial Therapies

Ancilia Biosciences, a pioneering biotechnology firm specializing in harnessing CRISPR technology for bacterial therapies, announced today the successful closure of an $4.2 million financing round. Safar Partners led the investment, joined by Metaplanet, Psymed Ventures, Zubi Capital, Spacecadet Ventures, and other institutional and private investors. The funding underscores the company’s commitment to leveraging CRISPR’s natural…

Read More

Linker Finance Secures $3.7 Million Seed Round to Revolutionize Digital Banking for Community Banks

Linker Finance, an innovative platform designed to enhance digital banking experiences for community banks, has successfully closed a $3.7 million seed funding round. The investment round was led by Ten One Ten Ventures and Chingona Ventures, with additional support from Audaz Capital, Techstars, Commerce Ventures, Bank of Brodhead, and Angeles Investors. Angel investors including Edrizio…

Read More

Citroniq Chemicals Secures $12 Million in Series A Funding to Advance Carbon-Negative Technology

Citroniq Chemicals LLC, a pioneer in producing carbon-negative materials, has successfully closed a $12 million Series A financing round. The funding was spearheaded by a major multinational energy technology firm renowned for providing large rotating equipment across the oil & gas, energy, and industrial sectors globally. Additional backing came from Lummus Technology Ventures and a…

Read More

Rainforest Secures $20 Million Series A Funding to Revolutionize Embedded Payments

Rainforest, a trailblazer in embedded payment solutions for software platforms, announced today the successful closure of an oversubscribed $20 million Series A funding round led by Matrix Partners. This funding, which also saw participation from Accel, Infinity Ventures, BoxGroup, The Fintech Fund, Tech Square Ventures, and Ardent Venture Partners, builds on Rainforest’s previous seed round,…

Read More

ThinkCyte Secures $32 Million in Series C Funding to Expand Global Reach of VisionSort™, Revolutionary AI-Driven Cell Sorting Technology

ThinkCyte Inc., a trailblazer in innovative cell analysis technology, has announced a significant milestone in its growth journey. The company has successfully closed a Series C funding round, raising $32 million in total, which includes an extension round of $15 million. This impressive funding round was spearheaded by the Japan Green Investment Corp. for Carbon…

Read More

DNA Nanobots Raises $3.5 Million to Advance Programmable, Non-Viral Gene Therapy Platform

DNA Nanobots, a biotechnology company pioneering self-assembling nanoscale therapeutics, has secured $3.5 million in funding from a prominent family office, strengthening its financial runway for the next 18 months. The investment marks a key step forward in advancing the company’s non-viral gene delivery platform toward clinical readiness. The funding represents a significant portion of DNA…

Read More